{"id":21049,"date":"2021-12-14T17:00:28","date_gmt":"2021-12-14T16:00:28","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/projects-actions-supported\/action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche\/"},"modified":"2025-04-11T11:32:41","modified_gmt":"2025-04-11T10:32:41","slug":"action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche","status":"publish","type":"page","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche\/","title":{"rendered":"Action 3 – Antibiotic Resistance network in partnership with low and middle income countries: development of 2 research projects"},"content":{"rendered":"\n
<\/div>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n

CircUs – Circulation of multidrug-resistant enterobacteria (MRE) in humans, animals and in the environment of rural, peri-urban and urban areas of developing countries: a “One Health” approach<\/h2>
\n

Coordinators:<\/strong> Eric CARDINALE (UMR Astre CIRAD, France), Nathalie GUESSEND (Antibiotics Unit, Institut Pasteur, C\u00f4te d\u2019Ivoire), Anne-Laure BA\u00d1ULS (UMR MIVEGEC, IRD, France), Abdou-Salam OUEDRAOGO (Souro Sanou University Hospital, Burkina Faso)<\/p>\n\n\n\n

Partner institutions:<\/strong> CIRAD, M\u00e9rieux Foundation; INSERM – IAME Unit; INSERM – UPSaclay; CEA and French National Reference Center for Carbapenem-Resistant Enterobacteriacae; Institut Pasteur of Cambodia; Institut Pasteur of C\u00f4te d\u2019Ivoire; National Reference Laboratory for Antimicrobials of C\u00f4te d\u2019Ivoire; Institut Pasteur of Madagascar; Institut Pasteur of Paris; IRD; National Reference Laboratory for Antimicrobials of Burkina Faso; National Agricultural Development Support Laboratory (LANADA) of C\u00f4te d\u2019Ivoire; Department of Infectious Diseases, University Hospital Joseph Raseta Befelatanana of Antananarivo, Madagascar.<\/p>\n\n\n\n

Partner countries:<\/strong> Burkina Faso, Cambodia, C\u00f4te d\u2019Ivoire, France and Madagascar<\/em><\/p>\n\n\n\n

Budget:<\/strong> \u20ac700k<\/p>\n\n\n\n

Summary<\/p>\n\n\n\n

The main objective of the project is to characterise the Antimicrobial Resistance (AMR) circulation, in particular concerning resistant Enterobacteriaceae strains responsible for urinary and digestive tract infections and bacteremia and the mobile genetic elements carrying these resistances. The study will be carried out in the three One Health sectors (human, animal and their environment) and in three types of habitats (urban, peri-urban, and rural).<\/p>\n\n\n\n

This project will be conducted in four partner countries: Burkina Faso, Cambodia, C\u00f4te d’Ivoire and Madagascar.<\/p>\n\n\n\n

The project aims to characterise the microbiological, epidemiological, genetic and metagenomic circulation of AMR in the ecosystem, to reinforce laboratory diagnostic and resistance surveillance capacities, and to establish specific recommendations for the management and use of antibiotics in the three studied habitats. As part of the Priority Research Programme on Antibiotic Resistance funding, an 18-month pilot study will be set up in order to assess the project overall functioning and its feasibility.<\/p>\n\n\n\n

This pilot phase will produce critical results for further development of the global project and will federate all the actors around common objectives. It will concurrently allow  strengthening of partnerships between member country organisations (such as national organisations under the Health Ministries and the Ministries in charge of livestock, research institutions ensuring of the study set up in the three habitats and the DNA extraction from bacterial isolates, and the Institut Pasteur of Paris that will centralise the data to sample sequencing, storage and analysis with all the partners).<\/p>\n\n\n\n

This first pilot study will thus allow capacity building that will ensure the development of a large scale study. Through this project, researchers will obtain a global and objective view of the AMR circulation in the concerned countries. Furthermore, this project will allow the implementation of antibiotic management and use measures that are tailored to the concerned countries and habitats, and more broadly in low and midle income countries.<\/p>\n<\/div><\/div>\n\n\n\n

RAMSES – Antimicrobial Resistance: Socio-Economic Factors and Regulations Influencing Emergence and Dissemination in Southern Countries<\/h2>
\n

Coordinators:<\/strong> Alexandre HOBEIKA (CIRAD, France), Ad\u00e8le KACOU N’DOUBA (University of Abidjan, C\u00f4te d\u2019Ivoire)<\/p>\n\n\n\n

Partner institutions:<\/strong> INRAE; IRD; Health Sciences Research Institute, Burkina Faso; Nazi Boni University, Higher Institute of Health Sciences, Burkina Faso; Institut Pasteur of Cambodia; Abidjan University, Department of Medical Sciences, C\u00f4te d\u2019Ivoire; Ministry of Agriculture, Livestock and Fisheries\/Veterinary Services, Madagascar; Institut Pasteur of Madagascar<\/p>\n\n\n\n

Partner countries:<\/strong> Burkina Faso, Cambodia, C\u00f4te d’Ivoire, France and Madagascar<\/em><\/p>\n\n\n\n

Budget:<\/strong> 300k\u20ac<\/p>\n\n\n\n

Summary<\/strong><\/p>\n\n\n\n

The RAMSES project aims to explore the socio-economic and regulatory factors which influence the emergence and spread of antimicrobial resistance (AMR), to understand the links between these factors and to identify levers for improved AMR surveillance and control actions in low- and middle-income countries. This project will document the socio-economic, institutional, and political factors driving antibiotic circulation as well as the risk management tools available for humans, animals, and the environment.<\/p>\n\n\n\n

The analysis framework will be mainly based on the study of the ” medicine social life ” (the trade economy and cultural norms of medicine prescription and use), and the public action sociology (the study of public policies, institutions, interest groups, science and controversies). The project will focus on a One Health approach (human, animal and environmental health).<\/p>\n\n\n\n

Data will be collected and processed by universities and research institutes in the four partner countries, Burkina Faso, Cambodia, C\u00f4te d\u2019Ivoire and Madagascar, and in different local contexts (urban, peri-urban and rural). The consortium gather researchers from the social, medical and veterinary sciences from France and partner countries.<\/p>\n\n\n\n

As part of the of the Priority Research Programme on Antibiotic Resistance funding, an 18-month pilot study will be set up in order to assess the project overall functioning and its feasibility.The overall project will provide public policy advices that take into account country-specific variations and public policy opportunities.<\/p>\n<\/div><\/div>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":139,"featured_media":0,"parent":11463,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"acf":[],"yoast_head":"\nAction 3 - Antibiotic Resistance network in partnership with low and middle income countries: development of 2 research projects - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Action 3 - Antibiotic Resistance network in partnership with low and middle income countries: development of 2 research projects - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-11T10:32:41+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche\/\",\"name\":\"Action 3 - Antibiotic Resistance network in partnership with low and middle income countries: development of 2 research projects - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"datePublished\":\"2021-12-14T16:00:28+00:00\",\"dateModified\":\"2025-04-11T10:32:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Projects and actions supported\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Action 3 – Antibiotic Resistance network in partnership with low and middle income countries: development of 2 research projects\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Action 3 - Antibiotic Resistance network in partnership with low and middle income countries: development of 2 research projects - French\u00a0National ANTIBIOTIC RESISTANCE Portal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche\/","og_locale":"en_GB","og_type":"article","og_title":"Action 3 - Antibiotic Resistance network in partnership with low and middle income countries: development of 2 research projects - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_modified_time":"2025-04-11T10:32:41+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche\/","name":"Action 3 - Antibiotic Resistance network in partnership with low and middle income countries: development of 2 research projects - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"datePublished":"2021-12-14T16:00:28+00:00","dateModified":"2025-04-11T10:32:41+00:00","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/action-3-reseau-avec-les-pays-a-ressources-limitees-du-ppr-antibioresistance-developpement-de-2-projets-de-recherche\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Projects and actions supported","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/projects-actions-supported\/"},{"@type":"ListItem","position":3,"name":"Action 3 – Antibiotic Resistance network in partnership with low and middle income countries: development of 2 research projects"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}}]}},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/pages\/21049"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=21049"}],"version-history":[{"count":9,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/pages\/21049\/revisions"}],"predecessor-version":[{"id":30273,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/pages\/21049\/revisions\/30273"}],"up":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/pages\/11463"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=21049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}